Welcome to MyStrategist.

MedTech Strategist's complimentary Community Blog focuses on the people and the passions that drive the global medical device industry. Sign up for our e-Newsletter to receive new articles and video interviews directly to your inbox.

e-Newsletter   Browse
Latest from Community Blog

MedTech Strategist's free Community Blog explores the passion behind the people, technologies, and companies impacting the global device space.


Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways

Start Trial
Latest from Community Blog

MedTech Strategist's free Community Blog explores the passion behind the people, technologies, and companies impacting the global device space.


Discover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with Market Pathways.

Subscribe   Free Premier Issue   Learn More
Latest from Community Blog

MedTech Strategist's free Community Blog explores the passion behind the people, technologies, and companies impacting the global device space.


ICYMI

Reducing Robotic Failures

While complications are extremely rare from robotic surgery failures, they have the potential to be catastrophic. Guidelines for reducing them, excerpted from our recent feature, “Safety in Spine Surgery.”

Discover the people, technologies, and companies in the global medical device industry that will impact your corporate strategy with MedTech Strategist.

Subscribe Now   Learn More

Latest from Community Blog

MedTech Strategist's free Community Blog explores the passion behind the people, technologies, and companies impacting the global device space.

Regulatory & Reimbursement

Pathways' Pick of the Week: TCET Timing

CMS signals its final Transitional Coverage for Emerging Technologies pathway could be published this month. Excerpted from Pathways' Picks July 10: TCET Timing, EU Reforms, Opioid Devices, and More.

Don't Just Advertise... Strategize!

Advertise with MedTech Strategist and be seen by medtech's most influential executives.

Learn More